Daily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
03 Jul 2023
03 Jul 2023
Historique:
medline:
10
7
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
epublish
Résumé
The potential association of low-volume paracentesis of less than 5 L with complications in patients with ascites remains unclear, and individuals with cirrhosis and refractory ascites (RA) treated with devices like Alfapump or tunneled-intraperitoneal catheters perform daily low-volume drainage without albumin substitution. Studies indicate marked differences regarding the daily drainage volume between patients; however, it is currently unknown if this alters the clinical course. To determine whether the incidence of complications, such as hyponatremia or acute kidney injury (AKI), is associated with the daily drainage volume in patients with devices. This retrospective cohort study of patients with liver cirrhosis, RA, and a contraindication for a transjugular intrahepatic portosystemic shunt who received either device implantation or standard of care (SOC; ie, repeated large-volume paracentesis with albumin infusion), and were hospitalized between 2012 and 2020 were included. Data were analyzed from April to October 2022. Daily ascites volume removed. The primary end points were 90-day incidence of hyponatremia and AKI. Propensity score matching was performed to match and compare patients with devices and higher or lower drainage volumes to those who received SOC. Overall, 250 patients with RA receiving either device implantation (179 [72%] patients; 125 [70%] male; 54 [30%] female; mean [SD] age, 59 [11] years) or SOC (71 [28%] patients; 41 [67%] male; 20 [33%] female; mean [SD] age, 54 [8]) were included in this study. A cutoff of 1.5 L/d or more was identified to estimate hyponatremia and AKI in the included patients with devices. Drainage of 1.5 L/d or more was associated with hyponatremia and AKI, even after adjusting for various confounders (hazard ratio [HR], 2.17 [95% CI, 1.24-3.78]; P = .006; HR, 1.43 [95% CI, 1.01-2.16]; P = .04, respectively). Moreover, patients with taps of 1.5 L/d or more and less than 1.5 L/d were matched with patients receiving SOC. Those with taps of 1.5 L/d or more had a higher risk of hyponatremia and AKI compared with those receiving SOC (HR, 1.67 [95% CI, 1.06-2.68]; P = .02 and HR, 1.51 [95% CI, 1.04-2.18]; P = .03), while patients with drainage of less than 1.5 L/d did not show an increased rate of complications compared with those receiving SOC. In this cohort study, clinical complications in patients with RA performing low-volume drainage without albumin infusion were associated with the daily volume drained. Based on this analysis, physicians should be cautious in patients performing drainage of 1.5 L/d or more without albumin infusion.
Identifiants
pubmed: 37410459
pii: 2806858
doi: 10.1001/jamanetworkopen.2023.22048
pmc: PMC10326647
doi:
Substances chimiques
Albumins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2322048Références
Hepatology. 2006 Dec;44(6):1535-42
pubmed: 17133458
J Hepatol. 2017 Nov;67(5):940-949
pubmed: 28645737
Am J Clin Oncol. 2020 Jan;43(1):14-19
pubmed: 31592807
J Hepatol. 2019 Jan;70(1):172-193
pubmed: 30144956
Aliment Pharmacol Ther. 2022 Sep;56(5):926-927
pubmed: 35934845
Gastroenterology. 1988 Jun;94(6):1493-502
pubmed: 3360270
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
JAMA Netw Open. 2020 Oct 1;3(10):e2017859
pubmed: 33104204
Gastroenterology. 1996 Oct;111(4):1002-10
pubmed: 8831595
Hepatology. 2020 Sep;72(3):1043-1055
pubmed: 31849085
J Hepatol. 2018 Mar;68(3):563-576
pubmed: 29111320
Hepatology. 2012 Apr;55(4):1172-81
pubmed: 22095893
Gut. 2015 Apr;64(4):531-7
pubmed: 25631669
Liver Transpl. 2017 May;23(5):583-593
pubmed: 28318147
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Aliment Pharmacol Ther. 2022 Aug;56(3):529-539
pubmed: 35656633
Clin Mol Hepatol. 2023 Jan;29(1):16-32
pubmed: 35676862
Liver Int. 2010 Aug;30(7):937-47
pubmed: 20492521
J Hepatol. 2016 Mar;64(3):574-82
pubmed: 26519600
J Hepatol. 2022 Apr;76(4):959-974
pubmed: 35120736
Hepatology. 2021 Aug;74(2):1014-1048
pubmed: 33942342
Am J Gastroenterol. 1997 Mar;92(3):394-9
pubmed: 9068457
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
J Hepatol. 2010 Sep;53(3):397-417
pubmed: 20633946
Gut. 1990 Feb;31(2):204-7
pubmed: 2311979
Palliat Support Care. 2019 Dec;17(6):677-685
pubmed: 30880658
Eur J Clin Invest. 1993 Sep;23(9):534-9
pubmed: 8243523
Hepatology. 1987 Jan-Feb;7(1):122-8
pubmed: 3804191
Aliment Pharmacol Ther. 2019 Sep;50(6):696-706
pubmed: 31373713
Hepatology. 1995 Sep;22(3):753-8
pubmed: 7657279
Eur J Gastroenterol Hepatol. 2017 May;29(5):539-546
pubmed: 28350743
Liver Int. 2019 Sep;39(9):1594-1607
pubmed: 31152623
Aliment Pharmacol Ther. 2020 Jul;52(1):107-122
pubmed: 32478917
Liver Int. 2006 Feb;26(1):46-54
pubmed: 16420509
Gastroenterology. 1997 Aug;113(2):579-86
pubmed: 9247479